25
total announcements
CHOKSILA.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 04 Nov 2026
Market Cap
₹141 Cr
P/E (TTM)
64.9
EPS (TTM)
₹3.11
52W Low
₹81.85
52W High
₹227.90
Dividend Yield
0.00%
Beta
0.29
Price / Book
5.5
Debt / Equity
133.6
Revenue (TTM)
₹47 Cr
Gross Margin
40.92%
Operating Margin
10.89%
Choksi Laboratories Ltd
Choksi Laboratories Ltd has received the Establishment Inspection Report (EIR) from the USFDA, indicating the closure of the inspection at its central laboratory in Indore.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has clarified on the delay in submission of the proceedings of the Extra-Ordinary General Meeting (EGM) held on October 17, 2026, stating that it was an unintentional error due to technical reasons and not a reflection of any misinformation about the company.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has informed that the proposed preferential issue of convertible warrants was not approved by shareholders and will not be proceeded with.
Choksi Laboratories Ltd
Choksi Laboratories Ltd held an EGM on 17th October 2026, where resolutions were not approved by the shareholders with requisite majority. The company submitted the voting results and a combined scrutinizer's report on remote e-voting and e-voting facility. The resolutions required special resolution, but the promoter and promoter group were not interested in the agenda/resolution.
Choksi Laboratories Ltd
Choksi Laboratories Ltd held an Extra Ordinary General Meeting (EGM) on October 17th, 2026, through video conferencing. The meeting was held to consider and approve a proposal for the issuance of convertible warrants on a preferential basis. The shareholders were provided with a remote e-voting facility, and the voting results will be announced within 48 hours.
Choksi Laboratories Ltd
Choksi Laboratories Ltd submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulation for the quarter ended 30.09.2026, confirming the dematerialization of securities and listing on stock exchanges.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has announced the closure of its trading window from October 1, 2026, till 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026. This is in compliance with SEBI regulations and the company's internal code of procedure and conduct.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has submitted a newspaper publication of a Notice of Extra-Ordinary General Meeting to be held through video conferencing on October 17, 2026, as per SEBI regulations.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has scheduled an Extra-Ordinary General Meeting (EOGM) on October 17, 2026, to consider the issue and allotment of convertible warrants on a preferential basis to the promoter and promoter group.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has approved the issuance and allotment of up to 3,50,000 convertible equity warrants to promoters, subject to shareholder approval.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has announced the voting results of its 33rd Annual General Meeting (AGM), where all resolutions were approved by the shareholders with the requisite majority. The company has also disclosed the details of the voting results for each business item.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 19/09/2026 to consider and approve the proposal for raising funds through issue of equity shares and/or any other equity-linked or convertible securities.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has submitted newspaper clippings for the notice of its 33rd Annual General Meeting to be held on September 18, 2026, through video conferencing.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has dispatched letters to shareholders whose email addresses are not registered with the company, informing them that the Annual Report for FY 2025-26 and the Notice of the 33rd AGM are available on the company's website.
Choksi Laboratories Ltd
Choksi Laboratories Ltd
Choksi Laboratories Ltd has submitted a notice convening its 33rd Annual General Meeting (AGM) to be held on September 18, 2026, through video conference or other audio-visual means. The meeting will consider the annual report and accounts for the financial year ended March 31, 2026. The notice is in compliance with SEBI regulations.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has informed that the USFDA inspected its central laboratory in Indore and raised 4 observations, which the company is addressing comprehensively.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has submitted a newspaper clipping related to the 33rd Annual General Meeting to be held through video conferencing, as per SEBI regulations.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has published unaudited financial results for the quarter ended 30th June, 2026, as per Regulation 47 of the SEBI (LODR) Regulations 2015.
Choksi Laboratories Ltd
Choksi Laboratories Ltd has announced the reappointment of Ms. Himika Choksi as Whole Time Director for a further period of five years, effective from 01.04.2027, subject to shareholder approval.